Arcutis Form 144: 3,172 Shares Listed for Sale

Arcutis Biotherapeutics submitted a Form 144 notice for the proposed sale of 3,172 shares of Common Stock, tied to restricted stock vesting on 05/01/2026.

Rhea-AI Filing Summary

Arcutis Biotherapeutics submitted a Form 144 notice for the proposed sale of 3,172 shares of Common Stock, tied to restricted stock vesting on 05/01/2026. The filing notes a prior sale of 37,349 shares on 03/02/2026 valued at $940,526.25.

Insights

Corporate Governance Analyst

Routine insider resale tied to vesting; prior large disposition shown.

The Form 144 lists a proposed sale of 3,172 shares associated with restricted stock vesting on 05/01/2026. Form 144s notify the market of intended sales by insiders and are procedural, not approval certificates.

Past dispositions include 37,349 shares sold on 03/02/2026 for $940,526.25. Timing and actual execution depend on broker activity and Rule 144 conditions.

Key Figures

Proposed shares to sell: 3,172 shares Shares sold in past 3 months: 37,349 shares Value of prior sale: $940,526.25 +1 more

4 metrics

Proposed shares to sell 3,172 shares restricted stock vesting on 05/01/2026

Shares sold in past 3 months 37,349 shares sale on 03/02/2026

Value of prior sale $940,526.25 aggregate value on 03/02/2026

Reported outstanding (listed) 124,033,382 figure shown in filing header (05/04/2026)

Key Terms

Form 144, Restricted Stock Vesting, Merrill Lynch

3 terms

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Vesting financial

"Common | 05/01/2026 | Restricted Stock Vesting"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Merrill Lynch market

"Common | Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH"

FAQ

What does Arcutis Biotherapeutics' Form 144 (ARQT) report?

Direct answer: It reports a proposed sale of 3,172 shares of common stock related to restricted stock vesting on 05/01/2026. Support: The filing also lists a prior sale of 37,349 shares on 03/02/2026 valued at $940,526.25.

Who is the reporting person on the Form 144 for ARQT?

Direct answer: The filing identifies an address linked to a reporting person and lists Todd F Watanabe in the past-sales section. Support: The excerpt shows a previous sale by Todd F Watanabe on 03/02/2026 of 37,349 shares.

How many shares were sold by insiders in the past three months for ARQT?

Direct answer: The filing records a past sale of 37,349 shares on 03/02/2026. Support: That transaction is shown with a value of $940,526.25 in the excerpt provided.

What brokerage is handling the proposed sale in the Form 144?

Direct answer: The excerpt lists Merrill Lynch and an associated address for the securities to be sold. Support: The broker line includes Merrill Lynch and an address at 8890 Lyra Drive, Columbus, OH in the filing text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 05:18 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801061
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Todd Watanabe
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	3172	74892.82	124033382	05/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			3172	05/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Todd F Watanabe 3027 Townsgate Rd Suite 300 Westlake Village CA 91361	Common	03/02/2026	37349	940526.25

144: Remarks and Signature

Remarks
Date of Notice	05/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Todd Watanabe
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)